Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances [Yahoo! Finance]
Agenus Inc. (AGEN)
Last agenus inc. earnings: 3/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
agenusbio.com/investors
Company Research
Source: Yahoo! Finance
Phase 3 on track to commence in fourth quarter 2025 LEXINGTON, Mass., November 10, 2025 BUSINESS WIRE Agenus Inc . (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government-funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO-GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial. Access & Regulatory France authorizes reimbursed AAC for BOT/BAL . In September, France's medicines agency (ANSM) authorized reimbursed compassionate access (Accès Compassionnel, AAC) for BOT/BAL in refractory MSS mCRC without active liver metastases—the first government-funded access for this population and the first reimbursed access provided for BOT/BAL by a regulatory agency. link Clinical Highlights BOT/BAL has demonstrated durable, long-
Show less
Read more
Impact Snapshot
Event Time:
AGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGEN alerts
High impacting Agenus Inc. news events
Weekly update
A roundup of the hottest topics
AGEN
News
- Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Agenus (NASDAQ:AGEN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL [Yahoo! Finance]Yahoo! Finance
- Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BALBusiness Wire
- Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC [Yahoo! Finance]Yahoo! Finance
AGEN
Earnings
- 11/10/25 - Miss
AGEN
Sec Filings
- 12/1/25 - Form 4
- 11/17/25 - Form 4
- 11/10/25 - Form 10-Q
- AGEN's page on the SEC website